Preclinical studies in animal models, such as EAE and DSS-induced colitis, have consistently demonstrated the efficacy of targeting metabolic nodes like mTOR, AMPK, HIF-1α, and PKM2 in rebalancing Th17/Treg responses. This evidence concerns the gene HIF1A and colitis.